Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma

Table 3 Kaplan-Meier survival estimates and multivariate cox regression comparing patients taking a combination of medications with patients on one or neither drug

Drug combination	Number of people on	Kaplan-Meier estimated median survival			Multivariate cox regression
	combination out of 164	For those on the drug combination	For those not on drug combination	P-value (log rank)	HR (95%CI)	P-value
CCB + aspirin	15	1414	528	0.012	0.300 (0.122-0.735)	0.008
CCB + statin	12	544	539	0.284	0.413 (0.155-1.101)	0.077
CCB + ACEI/ARB	12	485	541	0.450	0.512 (0.194-1.348)	0.175
Aspirin + statin	27	504	546	0.697	0.969 (0.509-1.844)	0.924
Aspirin + ACEI/ARB	22	485	569	0.923	0.948 (0.438-2.054)	0.893
Statin + ACEI/ARB	21	368	577	0.426	1.126 (0.533-2.379)	0.756

ACEI/ARB: Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; CCB: Calcium channel blockers.